Please login to the form below

Not currently logged in
Email:
Password:

tramiprosate

This page shows the latest tramiprosate news and features for those working in and with pharma, biotech and healthcare.

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

Earlier this week another drug in that category, Alzheon’s tramiprosate, also reported some encouraging data in a mid-stage trial, although that involved a subgroup of patients with a genetic

Latest news

  • Alzheon says data backs potential of Alzheimer's candidate Alzheon says data backs potential of Alzheimer's candidate

    The cognitive effect increased significantly with time, suggesting a potential disease-modifying effect of tramiprosate," they conclude. ... Tramiprosate is thought to work by inhibiting the aggregation of beta amyloid monomers into toxic oligomers.

  • Amyloid-targeting Alzheimer's drug bapineuzumab in phase III failure Amyloid-targeting Alzheimer's drug bapineuzumab in phase III failure

    The results have not come as a surprise, however, as several other drugs designed to target amyloid have already failed in trials - including Neurochem's Alzhemed (tramiprosate), Lundbeck/Myriad Genetics' Flurizan

  • 2012: amyloid as Alzheimer’s target?

    The number of disappointments for amyloid-targeting drugs is fairly substantial. Two small-molecule candidates, Neurochem's Alzhemed (tramiprosate) and Lundbeck/Myriad Genetics' Flurizan (r-flurbiprofen), failed a few years ago,

  • Signalling change

    Another once-promising anti-amyloid drug, tramiprosate, was also abandoned by Bellus Health due to inconclusive phase III study findings.

  • Halted in its tracks

    Tramiprosate is a B-amyloid inhibitor that is currently in phase III development with Neurochem. ... Data presented at ICAD 2006 showed tramiprosate halts B-amyloid-induced neuronal cell death in rats.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics